Medical Crossfire: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
WebcastFaculty
OVERVIEW
Medical Crossfire: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers is organized by Physicians Education Resource, LLC (PER) and will be held during May 30, 2017 - May 30, 2018.
The target audience for this medical event is including medical, radiation, and surgical oncologists whose primary practice focus is breast cancer. Participants will be primarily oncologists or fellows-in-training whose practices require mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the treatment and management of breast cancer. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, participants should be better prepared to:
• Explain tumor biology mechanisms that provide the rationale for targeting PARP in the treatment of cancers
• Assess emerging data concerning the application of PARP inhibitors in the treatment of breast cancer and how this applies to personalization of management/counseling for patients with these tumors and their families
• Apply lessons learned from PARP inhibitor strategies for ovarian cancer in the context of an evolving treatment landscape for patients with breast cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is including medical, radiation, and surgical oncologists whose primary practice focus is breast cancer. Participants will be primarily oncologists or fellows-in-training whose practices require mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the treatment and management of breast cancer. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, participants should be better prepared to:
• Explain tumor biology mechanisms that provide the rationale for targeting PARP in the treatment of cancers
• Assess emerging data concerning the application of PARP inhibitors in the treatment of breast cancer and how this applies to personalization of management/counseling for patients with these tumors and their families
• Apply lessons learned from PARP inhibitor strategies for ovarian cancer in the context of an evolving treatment landscape for patients with breast cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links